Clark Capital Management Group Inc. Raises Holdings in Cencora, Inc. $COR

Clark Capital Management Group Inc. boosted its position in Cencora, Inc. (NYSE:COR) by 0.9% in the 4th quarter, Holdings Channel reports. The fund owned 253,639 shares of the company’s stock after purchasing an additional 2,172 shares during the period. Clark Capital Management Group Inc.’s holdings in Cencora were worth $85,666,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. AustralianSuper Pty Ltd purchased a new stake in Cencora in the 3rd quarter worth approximately $26,191,000. Chilton Investment Co. Inc. purchased a new stake in Cencora in the 3rd quarter worth approximately $459,000. Lansforsakringar Fondforvaltning AB publ grew its stake in Cencora by 5.4% in the 3rd quarter. Lansforsakringar Fondforvaltning AB publ now owns 60,254 shares of the company’s stock worth $18,831,000 after acquiring an additional 3,073 shares during the period. Nordea Investment Management AB grew its stake in Cencora by 3.8% in the 4th quarter. Nordea Investment Management AB now owns 1,256,356 shares of the company’s stock worth $426,715,000 after acquiring an additional 45,712 shares during the period. Finally, Groupama Asset Managment purchased a new stake in Cencora in the 3rd quarter worth approximately $1,225,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Down 0.1%

Shares of COR opened at $281.22 on Wednesday. The firm has a market cap of $54.71 billion, a PE ratio of 21.57, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The company’s fifty day moving average is $287.49 and its two-hundred day moving average is $326.05. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the business earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its Board of Directors has approved a share repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. Cencora’s payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Morgan Stanley set a $342.00 target price on shares of Cencora in a research note on Friday, May 8th. Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Citigroup decreased their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Evercore set a $360.00 price target on shares of Cencora in a report on Wednesday, April 8th. Finally, Wells Fargo & Company decreased their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Twelve research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.